Protagonist Therapeutics announced FDA approval of ICOTYDE for moderate-to-severe plaque psoriasis in adults and adolescents, marking a major milestone with a $50 million payment. The oral peptide therapy targets the IL-23 receptor, offering a novel alternative to injectable treatments. Supported by extensive Phase 3 trials, the drug shows strong efficacy and safety, with Johnson & Johnson managing commercialization. Protagonist is exploring ICOTYDE's potential in other immune diseases and expects further milestones and royalties from its collaboration with Johnson & Johnson. Additional pipeline updates include an FDA decision expected for rusfertide in Q3 and ongoing development of oral therapies for immune and metabolic diseases.
Johnson & Johnson reported strong Q2 sales of $584 million for Spravato, a nasal spray for treatment-resistant depression, signaling robust market potential for psychedelic drugs. Jefferies highlights this growth supports the commercial viability of ...
Johnson & Johnson reported solid Q2 2026 results, achieving 6.6% annual revenue growth driven by strong Pharma and MedTech divisions. The company maintains a portfolio of over 15 blockbuster drugs and a promising pipeline, supporting its status as a ...
Johnson & Johnson reported better-than-expected Q2 2026 results with adjusted EPS of $2.90, surpassing estimates, and revenue of $25.31 billion, driven by strong pharmaceutical sales. Key growth came from the Innovative Medicine segment, with notable...
The FTSE 100 dropped 23 points to 10,506, pressured by mining stocks reacting to China's slower-than-expected 4.3% GDP growth in Q2, its weakest in three years. European markets also declined, while US futures rose, led by tech. PayPal shares surged ...
US stock futures rose after a softer-than-expected Consumer Price Index (CPI) report reduced the chances of a Federal Reserve rate hike in July. The market now awaits today's Producer Price Index (PPI) data, which could either confirm easing inflatio...
